PALISADE BIO, INC.
PALI · XNASCIK 1357459fmd_1C0QZF2KP408A7BG3RMFRSQ84YManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | – | 0 | 0 | 0 | 0 |
| Research and development | 13 | 8 | 4 | 4 | 3 | 2 | 7 | 7 | 16 | 10 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 21 | 14 | 9 | 9 | 9 | 42 | 16 | 13 | 15 | 18 |
| Operating income | (21) | (13) | (8) | (9) | (9) | (42) | (16) | (13) | (15) | (18) |
| Interest expense | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (2) | 3 | 0 | (1) | 15 | 1 | 1 | 0 | 1 |
| Income tax expense | 0 | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (21) | (16) | (5) | (8) | (10) | (27) | (14) | (12) | (14) | (17) |
| Net income to common shareholders | – | – | – | – | (10) | (27) | (15) | (12) | (14) | – |